The most recent ‘Scrip Asks’ instalments from the ‘What Does 2023 Hold For Biopharma’ series focuses on therapeutic area advances and includes an overview on the potential in CNS.
Our CEO/CSO Andrea Chicca is quoted:
“Following late-stage failures in neuropsychiatric and neurodegenerative diseases such as schizophrenia and Alzheimer’s a decade ago, several large pharma scaled back or exited the neuroscience field,” said Andrea Chicca, CEO and chief scientific officer of Synendos Therapeutics AG , which is developing endocannabinoid modulators for CNS disorders. “Now that is changing and we see real momentum building in neuroscience again with VC funding back to number two behind oncology”
The link to the Scrip article for subscribers is: https://bit.ly/3ZgbjG8
